Uploaded January 2026 | Updated November 2026, 15 hours ago
Presented By: Gulisa Turashvili, MD, PhD
Speaker Biography: Gulisa Turashvili, MD, PhD, is associate professor in the Department of Pathology and Laboratory Medicine at Emory University School of Medicine. An anatomic pathologist, Dr. Turashvili specializes in gynecologic and breast pathology...
Webinar:
Webinar Abstract: Gynecologic cancers account for nearly 40% of all cancer incidence and more than 30% of all cancer mortality in women worldwide. In recent years, there have been significant advancements in the classification of gynecologic tumors as well as the refinement of biomarker testing of prognostic and therapeutic significance. Human papillomavirus testing, DNA mismatch repair, HER2 and PD-L1 testing and homologous recombination testing have all seen advancements in recent years. It is the combination of an accurate histopathologic diagnosis and biomarker status that ensures timely and optimal therapy for each patient with gynecologic cancer...
Earn PACE Credits:
1. Make sure you’re a registered member of Labroots (labroots.com/)
2. Watch the webinar on YouTube or on the Labroots Website (labroots.com/webinar/gynecologic-prognostic-predictive-markers-era-precision-medicine?srsltid=AfmBOoprqjN70LN40Omr3HDQBlAFRo2qPe3ZOd-9ZscsrMrJhPVv4Hgy)
3. Click Here to get your PACE credits: (labroots.com/credit/pace-credits/8440/third-party)
Labroots on Social:
Facebook: facebook.com/LabRootsInc
Twitter: twitter.com/LabRoots
LinkedIn: linkedin.com/company/labroots
Instagram: instagram.com/labrootsinc
Pinterest: pinterest.com/labroots
SnapChat: labroots_inc
Presented By: Gulisa Turashvili, MD, PhD
Speaker Biography: Gulisa Turashvili, MD, PhD, is associate professor in the Department of Pathology and Laboratory Medicine at Emory University School of Medicine. An anatomic pathologist, Dr. Turashvili specializes in gynecologic and breast pathology...
Webinar:
Webinar Abstract: Gynecologic cancers account for nearly 40% of all cancer incidence and more than 30% of all cancer mortality in women worldwide. In recent years, there have been significant advancements in the classification of gynecologic tumors as well as the refinement of biomarker testing of prognostic and therapeutic significance. Human papillomavirus testing, DNA mismatch repair, HER2 and PD-L1 testing and homologous recombination testing have all seen advancements in recent years. It is the combination of an accurate histopathologic diagnosis and biomarker status that ensures timely and optimal therapy for each patient with gynecologic cancer...
Earn PACE Credits:
1. Make sure you’re a registered member of Labroots (labroots.com/)
2. Watch the webinar on YouTube or on the Labroots Website (labroots.com/webinar/gynecologic-prognostic-predictive-markers-era-precision-medicine?srsltid=AfmBOoprqjN70LN40Omr3HDQBlAFRo2qPe3ZOd-9ZscsrMrJhPVv4Hgy)
3. Click Here to get your PACE credits: (labroots.com/credit/pace-credits/8440/third-party)
Labroots on Social:
Facebook: facebook.com/LabRootsInc
Twitter: twitter.com/LabRoots
LinkedIn: linkedin.com/company/labroots
Instagram: instagram.com/labrootsinc
Pinterest: pinterest.com/labroots
SnapChat: labroots_inc










